Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Centrosomal protein of 78 kDa (CEP78) is a scaffold protein localized to the centrosome, required for regulation of centrosome-related events during the cell cycle and for the formation and control of primary cilia length (ciliogenesis)[1][3]. It possesses an N-terminal leucine-rich repeat (LRR) domain and a C-terminal coiled-coil domain[1][3]. CEP78 interacts with components of the EDD1-DYRK2-DDB1-VprBP E3 ubiquitin ligase complex, modulating ubiquitination and degradation of CP110, a key negative regulator of ciliogenesis, thereby influencing cilia biogenesis and centrosome homeostasis[1][2]. Loss-of-function mutations in CEP78 cause cone-rod dystrophy often associated with hearing loss (CRDHL) and other ciliopathy phenotypes, by impairing ciliation frequency and/or causing abnormal cilia length[1]. There are no known drugs that specifically interact with CEP78, and it is not considered a current therapeutic target[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Centrosomal protein of 78 kDa (CEP78).